Applicant: Wettstein et al. Attorney's Docket No.: 07039-0501US1 / 2003-089

Serial No.: 10/587,925

Filed: December 4, 2006

Page : 2 of 7

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the

application.

**Listing of Claims**:

1. (Original) A composition comprising a polypeptide and a CpG molecule, wherein said

polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-

interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid

sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-

interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG

molecule comprises at least one sulfur atom.

2. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence

further comprises at least one positively charged amino acid.

3. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence

comprises no more than 15 amino acid residues.

4-5. (Canceled)

6. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence

comprises a B-X, X-B, or B-X-B sequence, wherein B is a positively charged amino acid residue

and X is an amino acid residue.

7. (Withdrawn) The composition of claim 1, wherein said CpG-interacting amino acid sequence

comprises an B-X-B-X-B sequence, wherein B is a positively charged amino acid residue and X

is an amino acid residue.

Applicant: Wettstein et al. Attorney's Docket No.: 07039-0501US1 / 2003-089

Serial No.: 10/587,925

Filed: December 4, 2006

Page : 3 of 7

8-9. (Canceled)

10. (Withdrawn) The composition of claim 1, wherein at least one of said at least one cysteine

residue of said CpG-interacting amino acid sequence is adjacent to a positively charged amino

acid residue.

11. (Withdrawn) The composition of claim 10, wherein said CpG-interacting amino acid

sequence comprises the sequence set forth in SEQ ID NO:1 (KCSRNR).

12. (Withdrawn) The composition of claim 1, wherein said CpG-interacting amino acid

sequence consists essentially of the sequence set forth in SEQ ID NO:1 (KCSRNR).

13. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence

consists essentially of the sequence set forth in SEQ ID NO:2 (ACSANA).

14. (Withdrawn) The composition of claim 13, wherein said at least one positively charged

amino acid residue is an arginine.

15. (Withdrawn) The composition of claim 13, wherein said at least one positively charged

amino acid residue is a lysine.

16. (Original) The composition of claim 1, wherein said cytotoxic T lymphocyte-activating

amino acid sequence comprises no more than 50 amino acid residues.

17-19. (Canceled)

Applicant: Wettstein et al. Attorney's Docket No.: 07039-0501US1 / 2003-089

Serial No.: 10/587,925 Filed: December 4, 2006

Page : 4 of 7

20. (Original) The composition of claim 1, wherein said polypeptide is less than 50 amino acid residues in length.

21-23. (Canceled)

24. (Original) The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate linkage.

25-37. (Canceled)